HMGN2P17

Across TCGA pan-cancer cohorts, HMGN2P17 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated HMGN2P17 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher HMGN2P17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated HMGN2P17 expression acts as an unfavorable survival marker, although some lineages such as LUAD and OV show a favorable association.

ACC, LIHC, and LGG are the cancer types where HMGN2P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.228	0.706	<.001	126	view →
LIHC	OS	Median	All	0.622	0.748	.003	51	view →
LGG	DFS	Median	All	0.662	0.804	<.001	46	view →
LUAD	DFS	Quartile	III,IV	0.911	0.418	.001	40	view →
OV	OS	Median	IV	0.877	0.638	.002	34	view →
KIRP	DFS	Median	IV	0.039	0.623	.001	30	view →
CESC	OS	Tertile	IV	0.123	0.646	.028	24	view →
DLBC	DFS	Tertile	All	1.000	0.465	.014	20	view →
KICH	OS	Quartile	III,IV	0.159	0.814	.010	19	view →
KIRC	DFS	Median	II,III,IV	0.724	0.871	.006	18	view →
THCA	OS	Median	III,IV	0.988	0.899	.008	17	view →
UCEC	DFS	Tertile	All	0.486	0.767	<.001	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

HMGN2P17–ACC (DFS)

Open the ACC breakdown →